1. P-284Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): "first-in-cancer" phase Ib study. (2nd July 2019) Authors: Van Cutsem, E; Shitara, K; Deng, W; Vaury, A; Tseng, L; Wang, X; Millholland, J; Shilkrut, M; Mookerjee, B; Jonasch, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 921TiPAn open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma. (23rd October 2018) Authors: Jonasch, E; Park, E; Thamake, S; Hirmand, M; Srinivasan, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 884PReal-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study). (23rd October 2018) Authors: Procopio, G; Bamias, A; Schmidinger, M; Hawkins, R; Rodriguez Sanchez, A; Vazquez, S; Srihari, N; Kalofonos, H; Bono, P; Pisal, C; Hirschberg, Y; Dezzani, L; Ahmad, Q; Suarez Rodriguez, C; Jonasch, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗